首页 | 本学科首页   官方微博 | 高级检索  
检索        


Handling clinical comorbidity in randomized clinical trials in psychiatry
Institution:1. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA;2. Sierra Pacific Mental Illness, Research, Education and Clinical Centers (MIRECC), Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA;3. School of Psychology, University of Queensland, Brisbane, Australia;4. Geriatric Research, Education and Clinical Center (GRECC), Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA;5. Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
Abstract:The purpose of this paper is to a) outline the importance of including patients with clinical comorbidities in Randomized Clinical Trials (RCTs) of psychiatric treatments; and b) to propose a specific approach for best handling, analyzing and interpreting the data on clinical comorbidities in terms of their impact on treatment outcomes. To do this we first define and describe clinical comorbidity and differentiate it from other forms of comorbidity. We then describe the methodological and analytical problems associated with excluding patients with clinically comorbid conditions from RCTs, including the impact on the outcomes of RCTs in psychiatry and the impact on evidence-based clinical decision-making. We then address the challenges inherent to including patients with clinical comorbidities in RCTs. Finally, we propose a methodological and analytic approach to deal with these issues in RCTs which aims to significantly improve the information yielded from RCTs in psychiatry, and thus improve clinical decision-making.
Keywords:Clinical trials  Comorbidity  Multi-morbidity  Psychiatric disorders  Methodology  Clinical decision-making  Randomized control trials
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号